XLO 8-K: SEC filing

Xilio Therapeutics

Filed with the SEC on Nov 10, 2026 · accession 0001193125-26-454449

XLO filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Xilio Therapeutics announced its financial results for the quarter ended September 30, 2026, along with other business highlights, via a press release furnished as Exhibit 99.1 to its Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantXilio Therapeutics, Inc.

Chief legal officerBen Harshbarger

✦ Ask GOAX AI about this filing — what it means for XLO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for XLO?

Click here

Frequently asked questions

What did XLO file with the SEC on Nov 10, 2026?

XLO filed a 8-K (SEC filing). Xilio Therapeutics announced its financial results for the quarter ended September 30, 2026, along with other business highlights, via a press release furnished as Exhibit 99.1 to its Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other XLO SEC filings

Get alerts when XLO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

XLO overview XLO analysis XLO news Latest SEC filings